1,4,7,10- tetraazacyclododecane- 1,4,7,10- tetrakis(methylenephosphonic acid) (DOTMP)

01/01/2018 - "177 Lu-DOTMP has shown considerable promise as a metastatic bone pain palliating agent in preliminary evaluations and recent clinical studies. "
03/01/2018 - "Skeletal uptake of β- emitters of DOTMP complexes is used for the bone pain palliation. "
11/08/2016 - "Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation."
01/01/2018 - "Thus, 177 Lu-DOTMP induced apoptotic cell death in MG63 cells, which might be one of the primary causes of pain relief in osseous metastases."
01/01/2017 - "A "mix-and-use" approach for formulation of human clinical doses of 177 Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases."

11/01/2004 - "In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma."
11/01/2004 - "NeoRx STR 0303: a randomized multicenter study to compare the safety and efficacy of (166) HO-DOTMP plus melphalan to melphalan alone as conditioning for autologous peripheral blood stem cell transplant in subjects with primary refractory multiple myeloma."
10/01/2002 - "Thirty-two patients with multiple myeloma were treated with high doses of 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid (DOTMP) and were a subset of patients enrolled in a multicenter phase I/II dose escalation myeloablative trial. "
06/01/1995 - "The primary objective of this work was to estimate the absorbed dose distribution to the bone marrow of six multiple myeloma patients who received holmium-166 (166Ho) DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid) for the purpose of bone marrow ablation. "

08/01/2009 - "This pilot study was designed to determine the safety and efficacy of (166)Holmium (Ho)-DOTMP for irradiating malignant cells and adjacent marrow in women with bone-only metastatic breast cancer. "

01/01/2018 - "Thus, 177 Lu-DOTMP induced apoptotic cell death in MG63 cells, which might be one of the primary causes of pain relief in osseous metastases."
01/01/2017 - "A "mix-and-use" approach for formulation of human clinical doses of 177 Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases."
12/01/2016 - "The images represent the whole-body scans of a prostate cancer patient (man, 67 years) with skeletal metastases recorded after administering 3.7 GBq (100 mCi) of Lu-DOTMP."
01/01/2019 - "Ce-141-labeled DOTMP: A theranostic option in management of pain due to skeletal metastases."
01/01/2018 - "In this paper, the metal organic framework (MOF) concept is contributed to rearrange the bone-seeking agent composed of carrier-free lutetium-177 (Lu-177), 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraaminomethylenephosphonate (DOTMP) and cupper (II) (Cu (II)) for preparation of a potential agent for treatment of bone metastases. "

01/01/2019 - "These results demonstrate the potential utility of 141 Ce-DOTMP as a theranostic molecule for personalized patient care of cancer patients suffering from painful metastatic skeletal lesions."
09/01/2023 - "153 Sm-DOTMP (CycloSam® ) is a newly-patented radiopharmaceutical for bone tumor treatment. "
08/05/2019 - "Several compounds labelled with holmium-166 are now used in patients, such Ho166-labelled microspheres for liver malignancies, Ho166-labelled chitosan for hepatocellular carcinoma (HCC) and [166Ho]Ho DOTMP for bone metastases. "